Biomet Announces Senior Management Changes.

WARSAW, Ind. -- Biomet, Inc. (NASDAQ:BMET) today announced the appointment of Glen A. Kashuba to Senior Vice President of the Company and President of Biomet Trauma and Biomet Spine, effective April 17. With nearly twenty years of experience in the medical device industry, Mr. Kashuba most recently served as Worldwide President of Cordis Endovascular, a division of Johnson & Johnson. Mr. Kashuba has been with Johnson & Johnson since 1998, also holding the positions of Worldwide President of Codman Neuro Science and U.S. President of DePuy AcroMed, now known as DePuy Spine. Prior to his service with Johnson and Johnson, Mr. Kashuba held several key management positions during his eleven years with Howmedica.

Biomet's President and Chief Executive Officer Jeffrey R. Binder stated, "We are very pleased to announce the addition of Glen Kashuba to the Biomet management team. We are excited to welcome someone with Mr. Kashuba's level of experience and expertise and look forward to his contribution to the Biomet Trauma and Biomet Spine team."

Charles E. Niemier, formerly President of Biomet Trauma and Biomet Spine, has been named Senior Vice President, Biomet International and Corporate Relations. Mr. Niemier will be responsible for operations in Asia Pacific, Latin America and Canada, as well as having domestic responsibility for Corporate Clinical Relations, Contract Sales Administration, and Distributor Relations.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive devices; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.

Forward-Looking Statements 

This press release contains certain statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are qualified by the inherent risks and uncertainties surrounding future expectations generally, and also may materially differ from actual future experience involving any one or more of such statements. Such risks and uncertainties include our ability to develop and market new products and technologies in a timely manner, the effect of the pending merger on Biomet's business and its relationship with customers, distributors, employees and suppliers and the risk factors as set forth from time to time in Biomet's filings with the SEC. The inclusion of a forward-looking statement herein should not be regarded as a representation by Biomet that Biomet's objectives will be achieved. Biomet undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.